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Chicken chondrocytes in culture synthesize aggrecan proteo-
glycan as a 370 kDa precursor that is glycosylated and secreted
into the medium with a half-life of 30 min. In metabolic studies
the 370 kDa precursor was shown to render a degradation
intermediate of 190 kDa, which appeared with no measurable lag
phase; it was dependent on temperature (" 20 °C) and inhibited
by certain serine and serine}cysteine protease inhibitors such as
leupeptin and PMSF. By contrast, degradation was unaffected
by treatment of the cells with brefeldin A or with lysosomotropic
agents. Aggrecan precursors were detected by immunofluore-
scence analysis within a subcompartment of the endoplasmic
reticulum (ER), previously characterized as a smooth-membrane-
bound subregion [Vertel, Velasco, LaFrance, Walters and
INTRODUCTION
Proteins destined to enter the exocytic pathway are synthesized
in the endoplasmic reticulum (ER). Rough (ribosome-studded)
and smooth cisternae account for most of the ER which is
increasingly recognized to include a number of functionally
distinct subcompartments [1]. Distinct ER subcompartments
involved in protein glycosylation [2,3], virus assembly [4], re-
tention of misfolded or aggregated proteins [5–8] and Ca#+
regulation [9–11] have been described.
The ER is also the site where misfolded polypeptides or
unassembled subunits of multimeric proteins are degraded [12].
In general, proteins that fail to fulfil the requirements for
transport out of the ER can be degraded in this organelle. This
provides a mechanism for the early disposal of molecules not
meeting functional and}or conformational requirements. It is
also possible that cellular production of certain proteins is
regulated through control of synthesis and degradation rates in
the ER. However, it is unknown how these activities are co-
ordinated. One possibility is that proteolysis occurs in particular
subcompartments of the ER [13]. In a previous study we reported
that precursors of chondroitin sulphate (aggrecan) proteoglycans
accumulate in a specialized ER subcompartment of cultured
chondrocytes [14]. The present study demonstrates that degra-
dation of aggrecan precursors occurs in this subcompartment
and provides evidence for the compartmentalization of the
proteolytic activities within the ER.
MATERIALS AND METHODS
Antibodies and chemicals
Aggrecan monomers were purified from chick embryo sterna by
a previously published method [15] and used to immunize a
Abbreviations used: ER, endoplasmic reticulum; endo H, endo-b-N-acetylglucosaminidase H; endo D, endo-b-N-acetylglucosaminidase D; DTT,
dithiothreitol ; ALLM, N-acetyl-leucyl-leucyl-methioninal ; ALLN, N-acetyl-leucyl-leucyl-norleucinal.
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Kaczman-Daniel (1989) J. Cell Biol. 109, 1827–1836]. Analysis
of the subcellular fractions derived from chondrocytes indicated
that the degradation intermediate was concentrated in the ER
subcompartment. Degradation was dependent on the Ca#+ con-
centration and the redox state in the ER. Treatment of the cells
with agents or conditions that alter the degradation rate of
aggrecan precursors, such as protease inhibitors, decreased
temperature or dithiothreitol, also modified the retention of
these molecules in the ER subcompartment, as seen by immuno-
fluorescence. These results indicate that a fraction of the 370 kDa
aggrecan precursor is targeted to a smooth ER subcompartment
where it undergoes degradation.
rabbit. The antiserum was precipitated with 50% (NH
%
)
#
SO
%
and purified on an aggrecan–Sepharose 4B column. It recognized
aggrecan core protein in immunoblots and immunoprecipitates
of total cellular proteins. The antibody was further purified on
proteoglycan bands transferred to Immobilon P membrane
(Millipore, Bedford, MA, U.S.A.) as described by Olmsted [16]
using 0±2 M glycine, pH 2±8, to elute bound immunoglobulins
and 1 M Tris, pH 8±0, to neutralize eluents. A mouse monoclonal
antibody against keratan sulphate was purchased from ICN
Biochemicals (High Wycombe, Bucks., UK). Monoclonal
antibody against the KDEL sequence was a gift from Dr.
S. Fuller (European Molecular Biology Laboratory, Heidelberg,
Germany). Endoglycosidases H and D (endo H and D) were
purchased from Boehringer, Mannheim, Germany and chon-
droitinase ABC from Seikagaku Kogyo Co. Brefeldin A was from
Epicenter Technologies (Madison, WI, U.S.A.). Protease inhi-
bitors were obtained from either Sigma (St. Louis, MO, U.S.A.)
or Boehringer. Chloroquine, monensin, A23187, cycloheximide,
diamide, dithiothreitol (DTT), saponin and BSA were purchased
from Sigma.
Cell culture
Tissue culture products were purchased from Gibco}BRL
(Gaithersburg, MD, U.S.A.). Chondrocytes were isolated from
the sterna of 14-day-old chicken embryos as previously described
[3]. Cells were maintained in Ham’s F-12 medium supplemented
with 10% (v}v) foetal calf serum, 2 mM glutamine, 50 lg}ml
streptomycin and 50 units}ml penicillin. For metabolic labelling,
cells were maintained in suspension in 15 cm Petri dishes. Cells
for immunofluorescence were attached to gelatinized carbon-
coated coverslips. In both cases, cultures were fed with fresh
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medium every other day and 1 h before start of the experiments
on day 4.
Metabolic labelling and immunoprecipitation
Cells were recovered by centrifugation (1000 g for 10 min) and
treated with trypsin (5 min; 37 °C) to disrupt cellular aggregates.
For pulse–chase experiments, 0±5¬10' cells}ml were incubated
in methionine- and cysteine-free MEM medium (Sigma) con-
taining 10% (v}v) dialysed foetal calf serum for 20 min, pulsed
for 5 min in the same medium containing 200 lCi}ml Tran$&S-
label (1000–1100 Ci}mmol; ICN Radiochemicals, Cleveland,
OH, U.S.A.), and chased in complete medium containing a 100-
fold excess of both unlabelled methionine and cysteine. Cells and
media were separated by centrifugation (1000 g ; 10 min) and the
cell pellets were rinsed twice in cold PBS. Cells were then lysed
in 50 mM Tris}HCl buffer, pH 8±0, containing 400 mM NaCl,
5 mM EDTA, 1% (v}v) Triton X-100 and protease inhibitors
(5 mM benzamidine, 1 mM PMSF, 100 lg}ml soybean trypsin
inhibitor). Both media and postnuclear supernatants derived
from cell lysates were first cleared by incubation with preimmune
rabbit serum (1:40 dilution) for 1 h at room temperature followed
by 30 min incubation with preswollen Protein A–Sepharose
(10 mg}sample ; Sigma). Samples were centrifuged at 3000 g for
30 s and the supernatants transferred to new Microfuge tubes.
Antiserum against aggrecan was added (1:100 dilution) and the
incubation continued for 1 h at room temperature or overnight
at 4 °C. Samples were then incubated with Protein A–Sepharose,
as above. Immunoprecipitates from cell lysates were sequentially
rinsed three times in regular lysis buffer lacking protease inhibi-
tors, twice in lysis buffer containing 800 mM NaCl, and twice in
10 mM Tris}HCl buffer, pH 7±5. They were then denatured and
subjected to SDS}PAGE (5% acrylamide gels) and fluorography
as described [3]. Band intensities on autoradiographs were
determined by scanning densitometry using Molecular Dynamics
model 300A densitometer (Sunnyvale, CA, U.S.A.) ; data were
analysed using the ImageQuant Software (V 3±0, 1991; Molecular
Dynamics). In studies involving calculation of aggrecan intra-
cellular retention the 370 kDa precursor band localized on
autoradiograms from pulse-labelled cells was excised from dried
gels, rehydrated, dissolved in H
#
O
#
}NH
%
OH [17], and quantified
by scintillation counting. Immunoprecipitates from media were
washed as above, rinsed in 90% (v}v) acetone}10% (v}v) HCl,
dried overnight at 60 °C, and their radioactivity quantified by
scintillation counting. Endoglycosidase treatment of immuno-
precipitates was performed at 37 °C for 16 h as described [18].
Subcellular fractionation
All steps were performed at 4 °C. Radiolabelled chondrocytes
(10)–10* cells) were resuspended in a small volume (3–4 ml) of
10 mM Tris}HCl, pH 7±4, containing 10 mM KCl, 2±5 mM
MgCl
#
, 250 mM sucrose and 5 mM benzamidine. The cell
suspension was passed 9–12 times through a ball-bearing homo-
genizer (H & Y Enterprise, Redwood City, CA, U.S.A.) and then
centrifuged at 600 g for 10 min. The nuclear pellet was rinsed and
centrifuged again. Postnuclear supernatants were pooled and
centrifuged at 12000 g for 15 min. The postmitochondrial super-
natant was either incubated or not with 25 mM EDTA for 1 h
before centrifugation at 100000 g for 1 h (SW60 rotor ; Beckman
Instruments, Palo Alto, CA, U.S.A.). Microsomes were resus-
pended in 0±5 ml of 52% sucrose. This solution was placed on
top of a 61% sucrose cushion (0±5 ml) at the bottom of an SW60
ultracentrifuge tube. It was overlaid with 46% (0±5 ml), 38%
(0±5 ml), 30% (0±75 ml), 26% (0±75 ml) and 20% (0±5 ml) sucrose
solutions prepared in distilled water. Centrifugation was per-
formed at 120000 g for 12 h. Fractions (400 ll) were collected
from the bottom of the tube and used to determine both refrac-
tion index and RNA content. In addition, p-nitrophenyl-a-d-
mannosidase activity at pH 5±5 was determined as described by
Tulsiani et al. [19]. Membranes in each fraction were pelleted at
120000 g for 1 h in a TLA-100 ultracentrifuge (Beckman Instru-
ments). They were resuspended in 0±5 ml of 50 mM Tris}HCl
buffer, pH 8±0, containing 400 mM NaCl, 5 mM EDTA, 1%
(v}v) Triton X-100 and 1 mM PMSF and processed for aggrecan
immunoprecipitation, SDS}PAGE and fluorography.
Immunofluorescence microscopy
Monolayers of chondrocytes were rinsed twice in PBS. The
extracellular matrix was digested with 1 mg}ml hyaluronidase
for 10 min at 37 °C. Cells were then fixed in 3% formaldehyde in
0±1 M phosphate buffer, pH 7±2, for 30 min at room temperature.
Alternatively, cells were treated in a CO
#
incubator for 2 h at
37 °C with culture medium containing either DTT, cycloheximide
or protease inhibitors before fixation. In other experiments, the
cells were incubated at low (15 or 20 °C) temperature in medium
supplemented with 20 mM Hepes or at 37 °C for 3 h with
600 lg}ml rhodamine}ovalbumin (Molecular Probes Inc.,
Eugene, OR, U.S.A.) in serum-free medium. After fixation the
cells were rinsed in PBS, permeabilized with 0±05% (w}v) saponin
in PBS, and incubated with primary antibodies. Antibodies were
diluted in PBS}0±5% (w}v) BSA}0±05% (w}v) saponin. In-
cubation with antibodies was performed at room temperature
for 1 h. Primary antibodies were detected in a second incubation
step with either fluorescein-labelled goat anti-rabbit IgG or
rhodamine-labelled goat anti-mouse IgG (TAGO, Burlingame,
CA, U.S.A.). Unbound antibodies were washed out with PBS
and the coverslips were mounted in PBS}glycerol.
RESULTS
Identification of intracellular proteins related to aggrecan core
protein
Cultured chondrocytes were radiolabelled for 5 min with
Tran$&S-label, lysed and subjected to immunoprecipitation with
an antibody against aggrecanmonomer. The antibody recognized
a 370 kDa band previously described as the major aggrecan core
protein precursor present within cells (Figure 1A, lane 3) [20]. In
cells chased for 60 min with unlabelled methionine and cysteine
an additional band of 190 kDa was also recognized specifically
by the antibody (Figure 1A, lane 4). This protein was shown to
be immunologically related to the aggrecan molecule since it was
immunoprecipitated by affinity-purified antibody on the 370 kDa
band (Figure 1A, lane 5). Conversely, affinity-purified antibody
on the 190 kDa band also immunoprecipitated the 370 kDa
precursor (not shown). In cells chased for short times (10–15 min)
the crude polyclonal antibody also bound an additional 180 kDa
band which was not studied further. In contrast, other minor
bands were shown to be non-specific as they also appeared in
control samples incubated with preimmune serum (Figure 1A,
lane 2) or non-incubated with antibody (Figure 1A, lane 1). Only
aggrecan proteoglycans were immunoprecipitated from the me-
dium of pulse-labelled cultures chased for 60 min (Figure 1B,
lane 1). Their high molecular mass prevented them from entering
the stacking gel, which could be achieved after chondroitinase
treatment (Figure 1B, lane 2).
Intracellular degradation of aggrecan precursors
The processing of aggrecan core protein precursors was analysed
by pulse–chase experiments. Cells were metabolically labelled
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Figure 1 Specificity of the antibody against aggrecan proteoglycan
Chondrocytes were pulse-labelled with 200 lCi/ml Tran35S-label for 5 min and chased at 37 °C
for 60 min in the presence of unlabelled methionine and cysteine. (A) Lysates from both pulse-
labelled (lanes 1–3) and chased cells (lanes 4–5) were subjected to immunoprecipitation as
described in the Materials and methods section using no primary antibody (lane 1), preimmune
antiserum (lane 2), rabbit anti-aggrecan serum (lanes 3 and 4) or anti-aggrecan antibody
preabsorbed on Western blots containing the 370 kDa precursor (lane 5). (B) Immunoprecipitates
from the tissue culture medium of chased cells were incubated (lane 2) or not (lane 1) with
chondroitinase ABC before SDS/PAGE. The arrow indicates the limit between the stacking and
resolving gels.
with Tran$&S-label for 5 min and chased for different periods.
Aggrecan-related proteins were immunoprecipitated from both
cell lysates and culture medium using the anti-aggrecan antibody.
Newly synthesized aggrecan core protein precursor was detected
as a 370 kDa precursor that decreased with a half-life of approx.
25–29 min (Figure 2). Higher-molecular-mass forms appearing
at the top of the stacking gel probably represent heavily
glycosylated aggrecan monomers that were in the process of
being secreted from the Golgi complex. Accordingly, aggrecan
monomers were immunoprecipitated from the culture medium
with a half-life of 30 min (Figure 3). In addition, the 190 kDa
intracellular form increased transiently during the first 90 min of
the chase and then decreased gradually (half-life of 108 min)
(Figure 2A). This suggested the possibility that the 190 kDa
band represents a degradation intermediate derived from the
370 kDa precursor. In fact, only 73–75% of the total radio-
activity initially incorporated by the cells into the 370 kDa
precursor during a 5 min pulse was recovered from the culture
medium as $&S-aggrecan monomers after a 3 h chase period.
Therefore we inferred that 25–27% of the pulse-labelled aggrecan
precursors were retained intracellularly and that degradation
was probably the fate of these molecules since more than 98% of
them disappeared from within cells during this chase period. As
judged from the appearance of the 190 kDa intermediate, the
initial degradation step occurred with no apparent lag.
Serine/cysteine proteases degrade aggrecan precursors in a pre-
Golgi compartment
In order to determine whether the 190 kDa form was indeed a
degradation intermediate, we incubated pulse-labelled chon-
drocytes with different protease inhibitors at concentrations that
Figure 2 Pulse–chase analysis of de novo synthesized aggrecan core
protein precursors in cultured chondrocytes
Cells were pulse-labelled with 200 lCi/ml Tran35S-label for 5 min and chased in unlabelled
medium at 37 °C for the indicated time periods. Aggrecan precursors were immunoprecipitated
from cell lysates, resolved by SDS/PAGE, and detected by fluorography. Bands corresponding
to the 370 kDa precursor (D) and the 190 kDa intermediate (E) were located on
autoradiogram (A) and quantified by scanning densitometry (B). The limit between the stacking
and resolving gels is indicated (arrow). Values are plotted as a percentage of the maximal
amount of each molecular form found within cells. Data are representative of three different
pulse–chase experiments.
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Figure 3 Secretion of mature aggrecan molecules by cultured chondrocytes
Cells were pulse–chased as indicated in Figure 2. Secreted aggrecan monomers were
immunoprecipitated from the medium at various time points and quantified by scintillation
counting.
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Figure 4 Inhibition of aggrecan core protein intracellular degradation by
PMSF
Pulse-labelled chondrocytes were chased for 90 min at 37 °C in the presence of the indicated
concentrations of PMSF. Cell lysates and medium samples were immunoprecipitated with anti-
aggrecan antibody and processed as indicated in Table 1. Values are plotted as percentage
degradation inhibition compared with control cells incubated in chase medium with no inhibitor.
A similar curve was obtained for cells treated with leupeptin but in this case the concentrations
needed to achieve significant inhibition were two to three times lower.
do not affect cell viability. After a 90 min chase, aggrecan-related
molecules were immunoprecipitated from both cell lysates and
medium samples. Intracellular accumulation of the 370 kDa
aggrecan core protein precursor was taken as an indication of
degradation inhibition for those treatments that do not interfere
with secretion of aggrecan monomers in comparison with control
untreated cells. Thus degradation was substantially inhibited in
cells chased in the presence of certain serine}cysteine protease
inhibitors such as PMSF and leupeptin (Figure 4). Neither
PMSF nor leupeptin, however, inhibited secretion of mature
aggrecan monomers into the culture medium (Table 1). Degra-
dation inhibition was also observed with Tos-Lys-CH
#
Cl and
Tos-Phe-CH
#
Cl but these serine protease inhibitors also affected
processing and}or secretion of aggrecan monomers. In contrast,
degradation was unaffected by inhibitors of metalloproteases
(EDTA, phosphoramidon), cysteine proteases (ALLM and
ALLN), aminopeptidases (bestatin), acid proteases (chymostatin
and pepstatin A) or cathepsin A and B (antipain) (Table 1).
The cellular location of the 190 kDa intermediate was investi-
gated by testing the sensitivity of immunoprecipitated proteins to
treatment with endoglycosidases. Both the 190 kDa intermediate
and the 370 kDa aggrecan precursor were sensitive to endo H
treatment (Figure 5A, lane 3), but resistant to endo D treatment
(Figure 5A, lane 2). Since this is characteristic of glycoprotein
precursors that have not reached the Golgi complex [21,22], these
results indicated that degradation of the 370 kDa aggrecan
precursor giving rise to the 190 kDa intermediate occurred in a
pre-Golgi location. Further support for this conclusion was
obtained from experiments with cells chased in the presence of
brefeldin A. As shown in Figure 5(B), degradation still occurred
in the presence of brefeldin A indicating that it was not affected
by the disruption of the Golgi complex caused by this drug [23].
In addition, we examined whether degradation of aggrecan
Table 1 Effect of different protease inhibitors on the secretion and ER
degradation of aggrecan precursors
Cells (5¬106 for each treatment) were pulse-labelled with 200 lCi/ml Tran35S-label for 5 min
and chased for 90 min at 37 °C in the presence of one of the protease inhibitors indicated
below. Cell lysates and medium samples were subjected to immunoprecipitation with anti-
aggrecan antibody. Immunoprecipitates from cells were resolved by SDS/PAGE (same number
of counts per lane were loaded), detected by fluorography, and the 190 kDa and 370 kDa bands
analysed by scanning densitometry. Immunoprecipitates from tissue culture medium as well as
the 370 kDa band from the pulse sample were quantified by scintillation counting. Protein
retention was calculated by subtracting the amount of aggrecan secreted into the medium during
the chase period from the amount of 370 kDa precursor synthesized during the pulse. The
percentage of aggrecan retained intracellularly is shown. Inhibition of aggrecan degradation was
calculated as a decrease in the percentage of the p190 form with respect to the 370 kDa
precursor, compared with control cells incubated in chase medium with no inhibitor. Values for
the 370 kDa precursor were corrected for the intracellular accumulation of aggrecan precursors
observed in each treatment. ALLM, N -acetyl-leucyl-leucyl-methioninal ; ALLN, N -acetyl-leucyl-
leucyl-norleucinal. Data are representative of at least three different determinations.
Treatment
Protein
retention
(%)
Inhibition of
degradation
(%)
Control 27±0 0
EDTA (5 mM) 42±3 11±3
Phosphoramidon (200 lg/ml) 34±7 14±3
Aprotinin (20 lg/ml) 33±0 0
PMSF (1 mM) 30±0 45
Leupeptin (200 lg/ml) 33±3 53±1
Tos-Lys-CH2Cl (100 lM) 62±2 62±8
Tos-Phe-CH2Cl (20 lM) 64±8 35±3
Antipain (200 lg/ml) 34±2 15±5
ALLM (200 lg/ml) 49±0 13±5
ALLN (200 lg/ml) 22±0 3
Chymostatin (200 lg/ml) 37±4 11±7
Pepstatin A (200 lg/ml) 38±8 10±4
Bestatin (200 lg/ml) 27±2 0
Figure 5 Demonstration of intracellular degradation of aggrecan core
protein precursors in a pre-Golgi compartment
(A) Aggrecan-related proteins were immunoprecipitated from cell lysates of chondrocytes
labelled for 30 min with 200 lCi/ml Tran35S-label and subjected to digestion with endo-
glycosidases (H or D) or mock digested (C). Immunocomplexes were fractionated by SDS/PAGE
and detected by fluorography. (B) Autoradiogram showing aggrecan-related molecules
immunoprecipitated from pulse-labelled cells chased for 3 h at 37 °C in the presence of
2 lg/ml brefeldin A.
precursors was affected by pretreatment of the cells with agents
that interfere with endosome and lysosome function. Although
some accumulation of the 370 kDa precursor was observed in
cells preincubated with NH
%
Cl or chloroquine, this was probably
the result of a decreased rate of transport through the Golgi
(Table 2) rather than inhibition of degradation. Thus no signi-
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Table 2 Effect of various treatments on the ER degradation of aggrecan
precursors
Cells (5¬106 for each treatment) were metabolically labelled with 200 lCi/ml Tran35S-label
for 5 min and then incubated at 37 °C for 3 h in chase medium supplemented with the
compounds indicated below or incubated in chase medium at low temperature (15 or 20 °C).
Secreted aggrecan molecules were immunoprecipitated from the medium and quantified by
scintillation counting. Intracellular aggrecan-related molecules were also immunoprecipitated,
resolved by SDS/PAGE, detected by fluorography, and quantified by densitometric scanning of
autoradiograms. Data are means of three different experiments.
Protein
retention
(%)
Inhibition of
degradation
(%)
Control 26 0
Inhibition of ER-to-Golgi transport
Brefeldin A (2 lg/ml) 94±6 4
Monensin (100 lM) 56 27
Inhibition of lysosomal degradation
NH4Cl (50 lM) 71±5 13±4
Chloroquine (100 lM) 43 7
Energy-depletion treatments
20 mM NaN3­5 mM NaF 3±5 0
40 mM NaN3­10 mM NaF 30 0
Low-temperature incubations
15 °C 70 35
20 °C 44 37
Inhibition of protein synthesis
Cycloheximide (100 lg/ml) 23 21
Figure 6 Demonstration that lysosomotropic agents do not inhibit
intracellular degradation of aggrecan core protein precursors
Pulse-labelled cells (lane 1) were chased for 90 min at 37 °C in unlabelled medium containing
50 mM NH4Cl (lane 3), 100 lM chloroquine (lane 4) or 100 lM monensin (lane 5), agents
known to raise the intralumenal pH of lysosomes and endosomes and thus inhibit protein
degradation in these organelles. For comparison, cells similarly chased in control medium with
no inhibitor (lane 2) or in medium containing 200 lg/ml leupeptin (lane 6) were also
processed. Aggrecan-related proteins were immunoprecipitated from cells and subjected to
SDS/PAGE and fluorography.
ficant decrease in the 190 kDa intermediate was observed during
these treatments (Figure 6, lanes 2–5).
Degradation intermediates are concentrated in a specialized ER
subcompartment
It has been shown previously that aggrecan core protein pre-
cursors accumulate in a distinct smooth subregion of the ER
continuous with typical rough cisternae [14]. Therefore we
examined the possibility that degradation of aggrecan precursors
occurred in that subcompartment. The subcompartment was
identified by immunofluorescence analysis as peripheral vesicles
that did not stain with an antibody against keratan sulphate
Figure 7 Localization of aggrecan-related proteins in chondrocytes
Monolayers of chondrocytes were fixed and permeabilized (see the Materials and methods
section). Cells were processed for immunofluorescence by simultaneous staining with
antibodies against aggrecan (a, b), and either KDEL (a«) or keratan sulphate (b«). Alternatively,
before fixation, cells were incubated at 37 °C for 3 h in serum-free medium containing
600 lg/ml rhodamine/ovalbumin. They were then permeabilized and stained with anti-aggrecan
(c) to compare the intracellular distribution of aggrecan-related molecules with that of
endocytosed rhodamine/ovalbumin (c«). Arrows in each double-picture set indicate the locations
of ER subcompartments containing aggrecan precursors. Magnifications : ¬400.
(Figures 7b and 7b«), a glycosaminoglycan modification acquired
by aggrecan core protein precursors during their transport
through the Golgi complex [24]. The vesicles, however, did stain
with an antibody against theC-terminal sequenceKDEL (Figures
7a and 7a«), the retention signal for many ER lumenal proteins
[25]. The ER subcompartments containing aggrecan-related
molecules were readily distinguished from endosomes and lyso-
somes preloaded with endocytosed rhodamine}ovalbumin
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Figure 8 Concentration of intermediates derived from the intracellular
degradation of aggrecan precursors in an ER subcompartment
(A) Microsomes prepared from labelled chondrocytes (100 lCi/ml for 1 h continuous labelling)
were fractionated in a discontinuous sucrose gradient (^) as described in the Materials and
methods section. RNA content (D) and p -nitrophenyl (PNP)-a-D-mannosidase activity (E)
were determined. Fractions were subjected to immunoprecipitation with anti-aggrecan antibody.
Immunoprecipitates were processed for SDS/PAGE and fluorography, and the bands were
(Figures 7c and 7c«). In order to identify the aggrecan-related
molecules contained in the ER subcompartments, radiolabelled
chondrocytes were homogenized and fractionated in a discon-
tinuous sucrose gradient ; aggrecan-related proteins were then
immunoprecipitated from the different subcellular fractions and
analysed by SDS}PAGE and fluorography (Figure 8). Fractions
2–4 (specific gravity 1±24–1±17 g}ml) contained both the 190 kDa
intermediate and the 370 kDa precursor (Figure 8B). However,
when ribosomes were released from the microsomes with EDTA
[26], the 190 kDa degradation intermediate was still distributed
in the heaviest fractions of the gradient whereas the 370 kDa
precursor appeared additionally concentrated in fractions 5 and
6 (Figure 8C). Although only a small fraction (8–10%) of the
370 kDa precursors was usually displaced in the gradient by
EDTA treatment, the change in density was significant (from
Figure 9 Effect of Ca2+ depletion and the redox state on degradation of
aggrecan precursors in the ER
Chondrocytes were pulse-labelled for 5 min and chased at 37 °C for the indicated times. (A)
Cells were chased in unlabelled Ca2+-free medium containing (E) or not (D) 5 lM Ca2+
ionophore A23187. (B) Cells were chased in regular culture medium containing 1 mM DTT
(E), 1 mM diamide (^) or with no addition (D). Aggrecan-related proteins were
immunoprecipitated from cell lysates, fractionated by SDS/PAGE, and, after fluorography, the
190 kDa and 370 kDa bands quantified by scanning densitometry. The percentage of the
190 kDa degradation intermediate with respect to the 370 kDa precursor is shown. Data are
representative of three different experiments.
quantified by scanning densitometry. The distribution throughout the gradient of the 370 kDa
precursor (D) and the 190 kDa degradation form (E) is shown as percentage of the total
amount of each band recovered from the gradient for both control cells (B, C) and cells chased
in the presence of 100 lg/ml cycloheximide for 2 h (D). (C) corresponds to fractionated
microsomes from which ribosomes were previously released by incubation with 25 mM EDTA.
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Figure 10 Effect of several treatments on the intracellular localization of aggrecan-related molecules
Cells cultured as monolayers were incubated for 2 h either at 20 °C in regular culture medium (a) or at 37 °C in culture medium containing 100 lg/ml cycloheximide (b), 200 lg/ml ALLN (c),
200 lg/ml leupeptin (d) or 2 mM DTT (e). After fixation and permeabilization, cells were stained with antibody against aggrecan and processed for immunofluorescence as described in the Materials
and methods section. Magnifications : ¬350.
1±2 g}ml to 1±12 g}ml on average) and limited to this molecular
species. This suggested that the degradation intermediate was
confined within an organelle of similar buoyant density to, yet
distinct from, rough microsomes. In cells chased in the presence
of cycloheximide the only intracellular form of aggrecan was the
190 kDa degradation intermediate which remained in the
1±24–1±17 g}ml fractions (Figure 8D). This molecule was local-
ized by immunofluorescence analysis in the ER subcompartments
of cycloheximide-treated cells (see Figure 10b). Taken together
these results show that the ER subcompartment contained
intermediates resulting from degradation of the 370 kDa pre-
cursor, and suggest that the degradation event itself occurred in
that subregion of the ER.
Factors influencing degradation of aggrecan precursors in the ER
To determine conditions that promote or inhibit degradation of
the 370 kDa precursor in the ER we chased the cells under
different conditions after a short (5 min) pulse. It has been
reported that changes in the Ca#+ concentration of the ER lumen
interfere with degradation of proteins retained in this organelle
[27–29]. As shown in Figure 9(A), incubation of the cells with the
Ca#+ ionophore A23187 caused a 5-fold decrease in the degra-
dation rate whereas the amount of aggrecan proteoglycans
secreted into the medium was increased by about 10% compared
with control untreated cells. Likewise, ER degradation of ag-
grecan precursors was dependent on the redox state of the ER
lumen. Degradation of the 370 kDa precursor was stimulated by
the reducing agent DTT and it was partly inhibited by diamide,
a permeant thiol-oxidizing reagent (Figure 9B). These two agents
affected in a similar way proteoglycan secretion as they both
caused little retention of aggrecan precursors within cells (33%
compared with 26% retention in control cells). In addition, in
cells incubated with the alkylating agent N-ethylmaleimide,
degradation was 70% inhibited (not shown). In keeping with
recent reports [28,30,31], these observations suggest that free
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thiol groups are needed for optimal ER degradation. They are
also consistent with the possible role of serine}cysteine proteases
in ER degradation of aggrecan precursors (Figure 4, Table 1).
On the other hand, degradation was inhibited by low temperature
and was insensitive to energy depletion by NaN
$
and NaF
treatment (Table 2). As shown above, cycloheximide did not
significantly inhibit the appearance of the 190 kDa degradation
intermediate (Figure 8C); but it did inhibit further proteolysis of
this molecular form as it remained within the ER degradation
subcompartment for long periods (Figure 10b).
Degradation occurs within the ER smooth subcompartment
We took advantage of the above findings showing degradation
enhancement or inhibition under different incubation conditions
to examine the effects of these treatments on the morphological
localization of aggrecan-related molecules by immunofluore-
scence (Figure 10). Aggrecan-related molecules were clearly
detected in fluorescent vesicles, equivalent to ER sub-
compartments, in cells exposed to conditions that inhibit degra-
dation such as incubation at low temperature (Figure 10a) or
with leupeptin (Figure 10d). In fact, we observed a significant
increase in the number and size of the vesicles with some of these
inhibitory treatments (compare, for example, Figures 10c and
10d), probably resulting from accumulation of the 370 kDa
precursor (Figure 4, Table 2). In contrast, ER subcompartments
containing aggrecan-related molecules were scanty in cells treated
with DTT which, as indicated above, induces a 2-fold increase in
the degradation rate (Figure 10e). It can be concluded from these
observations that degradation is preceded by transport of the
370 kDa precursor into the smooth ER subcompartment. Thus
inhibition of degradation results in accumulation of intact
precursors within this compartment.
DISCUSSION
In this study we have examined the intracellular degradation of
aggrecan core protein precursors synthesized by cultured chicken
chrondrocytes. Our data indicate that, during the processing of
the initial 370 kDa aggrecan core protein precursor, a 190 kDa
degradation intermediate is normally generated. A 180 kDa
fragment was also detected in some experiments but its re-
lationship to the aggrecan core protein molecule could not be
unequivocally demonstrated.
Both subcellular fractionation and immunolocalization experi-
ments indicate that degradation of the aggrecan core protein
precursors occurs within an ER smooth subcompartment pre-
viously described in this cell type [14]. After ribosome release
from microsomal membranes, the 190 kDa degradation inter-
mediate was found in a smooth-membrane fraction distinct from
those fractions containing exclusively the 370 kDa precursor. In
cycloheximide-treated chondrocytes, the membrane fraction con-
taining the degradation intermediate corresponded to the ER
subcompartments detected by immunofluorescence in these cells
(Figures 8D and 10b). In addition, inhibition of the degradation
process induced accumulation of the 370 kDa precursor and this
was morphologically noted as an increase in the number and size
of the ER subcompartments. The simplest explanation for these
observations is that a fraction (estimated to be 25–27%) of
aggrecan precursors is continually targeted for degradation into
a specialized ER smooth subcompartment. Alternatively, ER
degradation of aggrecan precursors is not restricted to a par-
ticular subregion in the organelle. This possibility, however, is
not supported by our observation that an increase in the
degradation rate of aggrecan precursors correlated with a de-
crease in their presence in ER subcompartments in chondrocytes
treated with DTT (Figures 9B and 10e).
Protein degradation is considered to be part of the quality-
control system in the ER [12], providing an efficient way of
disposing of polypeptides incompetent for transport to the cis-
Golgi. This system is very selective, since only misfolded proteins
or unassembled subunits are degraded [18,32]. Compart-
mentalization of the degradation reactions decreases the possi-
bility of interference with other events occurring in the ER and
provides a means of optimizing degradation reactions. Both the
segregation of proteolytic enzymes and their substrates and the
control of the ionic and pH conditions in the degradation
compartments could favour rapid proteolysis. A specialized
subcompartment could also be the site where the cytosolic and
ER proteolytic pathways converge [33,34]. Properly folded and
assembled proteins could avoid degradation by not being targeted
to these compartments. However, other alternatives are also
possible. For instance, compartmentalization might be unnecess-
ary if the degradation machinery were highly selective and able
to distinguish misfolded proteins from correctly folded molecules.
The factors that determine degradation of some aggrecan
precursors in the ER are unknown. One can speculate that the
precursors to be degraded are misfolded or underglycosylated
proteoglycans actively retained in the ER. In fact, retention of
some 370 kDaprecursorswas noted in previous studies describing
aggrecan biosynthesis and processing by cultured chick chondro-
cytes [35]. In addition, we have observed association of the
aggrecan precursors contained in ER subcompartments with the
chaperone immunoglobulin-heavy-chain-binding protein (BiP)
(M. Alonso and A. Velasco, unpublished work), which is per-
manently bound to misfolded and incompletely assembled pro-
teins [36]. Alternatively, degradation could result from non-
stoicheiometric production of aggrecan precursors and other
extracellular matrix proteins. For instance, intracellular inter-
action between aggrecan core protein and link protein has been
proposed to explain the co-ordinated synthesis of these two
molecules by chondrocytes [35]. Lack of association with link
proteins in the ER could leave some aggrecan precursors
unprotected from degradation. A similar situation was recently
described in cells overexpressing the major histocompatibility
complex class I molecules in the absence of antigenic peptides.
Before degradation these proteins become accumulated in an
expanded ER subcompartment [13]. It is also possible that an
excess of aggrecan precursors forms insoluble aggregates in the
lumen of the ER degradation compartment, as is found in
cobalt-treated pancreatic cells [5] and thyroxine-treated thyro-
trops [37].
The existence of degradative compartments in the ER extends
the number of functionally distinct subcompartments and sup-
ports the view that the ER is a compartmentalized organelle [1].
Each event in protein biosynthesis, i.e. translation, subunit
assembly, glycosylation, degradation, etc., could potentially be
localizedwithin a specializedER subregion. Further investigation
is necessary to elucidate the mechanisms by which this compart-
mentalization is maintained.
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